LIVE Programme
CET Time
Sunday, January 31, 2021
13:30-14:30 2 Simultaneous Meet the Expert Sessions
Treatment of higher risk MDS Mikkael Sekeres (Miami)
Treatment of lower risk MDS Lionel Adès (Paris)
SESSION VIII – Future Treatments and Treatment Strategies in MDS?
Chair: Pierre Fenaux (Paris)
14:35-14:40 Introduction Pierre Fenaux (Paris)
14:40-14:55 Regulatory issues: registration of drugs in haematology Axel Glasmacher (Bonn)
14:55-15:25 ROUNDTABLE:
Current MDS/CMML clinical trials in Europe
Speakers: Valeria Santini (FISM), David Valcárcel (GESMD), Pierre Fenaux (GFM),
Uwe Platzbecker (GMDS and EMSCO)
15:25-15:40 How to target CHIP? Klaus Metzeler (Leipzig)
SHORT COMMUNICATION:
15:40-15:50 Cellular and Murine-PDX Models to Evaluate New Therapies Tomáš Stopka (Prague)
for Azacitidine-Resistant MDS
15:50-16:20 Panel discussion
SESSION IX – Late-Breaking talks
Chair: Pierre Fenaux (Paris)
16:20-16:25 Introduction Pierre Fenaux (Paris)
16:25-16:40 Vexas syndrome and MDS David Beck (Bethesda)
16:40-16:55 MDS/CMML with TET2 or IDH mutations are associated with Lin-Pierre Zhao (Paris)
Systemic Inflammatory and Autoimmune Diseases and T-cell
Dysregulation
16:55-17:25 Panel discussion
17:25 Closing Remarks Chairs
*Pending confirmation
6
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES